High Phase 3 failure risk

Bearish

A pharma ticker's most urgent Phase 3 trial has a Bayesian failure probability well above the base rate.

PRIMARY SOURCE
Hay 2014
DiMasi 2016
TYPICAL HORIZON
until primary completion (typically 3-12 months)
FACTORS USED
none (universe baseline)

What it means

A biotech or pharma company with a single-asset pipeline where the next Phase 3 readout will dominate price action for the coming year. Our Bayesian engine combined the base failure rate (~42% for Phase 3) with signals like enrollment velocity, endpoint amendments, mechanism of action risk, and cash burn, and arrived at a failure probability materially above the prior.

Why it works

Hay 2014 industry data show ~58% of Phase 3 trials fail. The LLR-based combination of live signals lets us update that base rate with current trial-specific evidence — enrollment anomalies, endpoint amendments mid-trial, historically high failure-rate mechanisms of action. The resulting posterior is directly tradeable because Phase 3 readouts cause ±30-50% price moves and dominate the ticker's next 6-12 months.

Watch out

Binary event. If the trial actually succeeds, the bearish thesis reverses completely and the ticker typically gaps up 30-80% on readout day. This pattern is about probability-weighted expected return, not directional certainty. Position-size accordingly.

Live matches

14 tickers firing right now
TickerCompanySectorChangeScore
SRPTSarepta TherapeuticsHealthcare-1.62%50[5–95]CSL.AXCSL LimitedHealthcare-0.09%43[5–95]NOVO-B.CONovo NordiskHealthcare-1.47%42[5–94]ALKSAlkermes plcHealthcare+3.08%42[5–94]GSKGSK plcHealthcare-1.34%41[5–93]NVONovo NordiskHealthcare-3.12%41[5–93]ISRGIntuitive SurgicalHealthcare-2.23%40[5–92]GSK.LGSK plcHealthcare-0.59%39[5–91]UCB.BRUCB S.A.Healthcare-0.59%39[5–91]BIIBBiogen Inc.Healthcare-0.34%36[5–88]4568.TDaiichi SankyoHealthcare-0.09%35[5–87]VRTXVertex PharmaceuticalsHealthcare+0.42%35[5–87]068270.KSCelltrion Inc.Healthcare-2.58%34[5–86]BMRNBioMarin PharmaceuticalHealthcare+4.99%32[5–84]
Disclaimer. Pattern matches are research signals, not investment advice. Past performance of an academic effect does not guarantee future returns. Forward-return tracking for Framler's own implementation begins 2026-05-16 after the calibration window closes.
More from Framler
Pattern library →How patterns compose with Framler →Framler framework paper →Per-pattern hit rate (post-16-May) →Sector rotation overview →Math invariants live →